Skip to main content

Drug Interaction Report

5 potential interactions and/or warnings found for the following 5 drugs:

Add another drug
Filter by interaction and/or warning

Interactions between your drugs

Moderate

potassium chloride etodolac

Applies to: potassium chloride, etodolac

MONITOR: Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.

MANAGEMENT: Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.

References

  1. Product Information. SSKI (saturated) (potassium iodide). Upsher-Smith Laboratories Inc.
  2. Product Information. K-Phos Original (potassium acid phosphate). Beach Pharmaceuticals. 2002.
  3. Cerner Multum, Inc. Australian Product Information.
  4. Product Information. Potassium Chloride (potassium chloride). Pharmaceutical Assoc Inc Div Beach Products. 2016.
  5. Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc. 2018.
  6. Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate). Patrin Pharma. 2018.
View all 6 references

Switch to consumer interaction data

Moderate

magnesium sulfate cholecalciferol

Applies to: magnesium sulfate, Vitamin D3 (cholecalciferol)

GENERALLY AVOID: Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to potentially additive pharmacologic effects. Chronic hypermagnesemia may have a role in the pathogenesis of adynamic bone disease in dialysis patients.

MANAGEMENT: Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.

References

  1. Product Information. Rocaltrol (calcitriol). Roche Laboratories. 2001;PROD.
  2. Product Information. Zemplar (paricalcitol). Abbott Pharmaceutical. 2001;PROD.
  3. Product Information. Hectorol (doxercalciferol). Genzyme Corporation. 2004.
  4. Product Information. One-Alpha (alfacalcidol). Pharmel Inc. 2004.
View all 4 references

Switch to consumer interaction data

No other interactions were found between your selected drugs. However, this does not necessarily mean no other interactions exist. Always consult your healthcare provider.

Drug and food interactions

Moderate

calcium carbonate food

Applies to: calcium carbonate

ADJUST DOSING INTERVAL: Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.

MANAGEMENT: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.

References

  1. Cerner Multum, Inc. UK Summary of Product Characteristics.
  2. Canadian Pharmacists Association. e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink 2006.
  3. Cerner Multum, Inc. Australian Product Information.
  4. Agencia Española de Medicamentos y Productos Sanitarios Healthcare. Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html 2008.
  5. Mangels AR. Bone nutrients for vegetarians. Am J Clin Nutr. 2014;100:epub.
  6. Davies NT. Anti-nutrient factors affecting mineral utilization. Proc Nutr Soc. 1979;38:121-8.
View all 6 references

Switch to consumer interaction data

Moderate

etodolac food

Applies to: etodolac

GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.

MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.

References

  1. Product Information. Motrin (ibuprofen). Pharmacia and Upjohn. 2002;PROD.

Switch to consumer interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Nutritionals

Therapeutic duplication

The recommended maximum number of medicines in the 'nutritionals' category to be taken concurrently is usually three. Your list includes four medicines belonging to the 'nutritionals' category:

  • calcium carbonate
  • magnesium sulfate
  • potassium chloride
  • Vitamin D3 (cholecalciferol)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer